Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 23, 2026Annals of HematologyOpen Access

Brentuximab vedotin combined with risk-adapted chemoimmunotherapy for Hodgkin’s lymphoma in Chinese children: a single-center, nonrandomized controlled study

View Full Paper
Ask AI
Bookmark
Share

Authors

段段彦龙HGHuixia GaoNLNan Li

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

段彦龙 et al. (2026) studied this question.

synapsesocial.com/papers/6ab39dc64f6cc12e38b514cbhttps://doi.org/10.1007/s00277-026-07273-w
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Tumor-Specific Immune Responses and Biomarkers in pediatric High-Risk Hodgkin Lymphoma Patients2025 · 3 citations
  2. 2Treatment of children with relapsed and refractory classical Hodgkin’s lymphoma: the experience of two centers2024
  3. 3Treatment Outcomes With Novel Targeted and Immunotherapeutic Regimens in CAYA Hodgkin Lymphoma: A Retrospective Study2026
  4. 4Real-world, multicenter study of brentuximab vedotin-based regimens in Chinese patients with relapsed/refractory Hodgkin lymphoma2025
  5. 5A systematic literature review of clinical evidence and treatment burden in newly diagnosed high‐risk pediatric patients with classical Hodgkin lymphoma2024 · 3 citations